Everett Meyer
Concepts (232)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Graft vs Host Disease | 18 | 2026 | 278 | 7.580 |
Why?
| | Hematopoietic Stem Cell Transplantation | 23 | 2026 | 698 | 6.490 |
Why?
| | T-Lymphocytes, Regulatory | 13 | 2026 | 407 | 4.850 |
Why?
| | Islets of Langerhans Transplantation | 3 | 2025 | 70 | 2.370 |
Why?
| | Transplantation Conditioning | 5 | 2026 | 191 | 2.210 |
Why?
| | Forkhead Transcription Factors | 4 | 2026 | 207 | 1.820 |
Why?
| | Graft Rejection | 5 | 2025 | 518 | 1.740 |
Why?
| | Transplantation, Homologous | 12 | 2026 | 417 | 1.450 |
Why?
| | Graft Survival | 6 | 2025 | 517 | 1.250 |
Why?
| | Cytokine-Induced Killer Cells | 2 | 2020 | 2 | 1.220 |
Why?
| | Tissue Donors | 6 | 2025 | 419 | 1.120 |
Why?
| | Lymphocyte Activation | 7 | 2026 | 1131 | 1.120 |
Why?
| | Immune Tolerance | 3 | 2021 | 385 | 1.080 |
Why?
| | Lymphatic Irradiation | 2 | 2025 | 11 | 1.080 |
Why?
| | Bone Marrow Transplantation | 4 | 2025 | 297 | 1.010 |
Why?
| | Transplantation Tolerance | 3 | 2025 | 39 | 1.010 |
Why?
| | T-Lymphocytes | 10 | 2025 | 1993 | 1.000 |
Why?
| | Transplantation Chimera | 2 | 2025 | 57 | 0.940 |
Why?
| | Hematologic Neoplasms | 5 | 2026 | 168 | 0.940 |
Why?
| | CD3 Complex | 1 | 2025 | 112 | 0.900 |
Why?
| | CD4-Positive T-Lymphocytes | 6 | 2026 | 1138 | 0.900 |
Why?
| | Whole-Body Irradiation | 1 | 2025 | 74 | 0.890 |
Why?
| | Natural Killer T-Cells | 4 | 2020 | 71 | 0.840 |
Why?
| | Apyrase | 1 | 2024 | 27 | 0.840 |
Why?
| | Myelodysplastic Syndromes | 1 | 2026 | 148 | 0.820 |
Why?
| | Leukemia | 1 | 2026 | 246 | 0.790 |
Why?
| | Bronchial Hyperreactivity | 8 | 2010 | 104 | 0.790 |
Why?
| | Bridged Bicyclo Compounds, Heterocyclic | 1 | 2025 | 280 | 0.780 |
Why?
| | Sulfonamides | 1 | 2025 | 583 | 0.690 |
Why?
| | Hepatitis A Virus Cellular Receptor 1 | 2 | 2019 | 43 | 0.630 |
Why?
| | Myeloproliferative Disorders | 1 | 2019 | 21 | 0.580 |
Why?
| | Immunomodulation | 1 | 2020 | 99 | 0.580 |
Why?
| | Killer Cells, Natural | 5 | 2015 | 478 | 0.580 |
Why?
| | Autoimmunity | 2 | 2025 | 932 | 0.540 |
Why?
| | Antibodies | 1 | 2020 | 397 | 0.530 |
Why?
| | Cytotoxicity, Immunologic | 3 | 2024 | 224 | 0.500 |
Why?
| | T-Lymphocyte Subsets | 4 | 2024 | 417 | 0.480 |
Why?
| | Receptors, Antigen, T-Cell, alpha-beta | 2 | 2020 | 333 | 0.480 |
Why?
| | Biomarkers | 3 | 2026 | 4282 | 0.450 |
Why?
| | Tacrolimus | 2 | 2026 | 195 | 0.400 |
Why?
| | Mice, Inbred BALB C | 9 | 2025 | 1261 | 0.400 |
Why?
| | Animals | 25 | 2026 | 37952 | 0.390 |
Why?
| | Complementarity Determining Regions | 1 | 2013 | 54 | 0.390 |
Why?
| | Humans | 35 | 2026 | 145140 | 0.390 |
Why?
| | Gastrointestinal Microbiome | 1 | 2020 | 766 | 0.360 |
Why?
| | Mice | 19 | 2025 | 18303 | 0.360 |
Why?
| | Antibodies, Monoclonal | 1 | 2019 | 1505 | 0.360 |
Why?
| | Asthma | 7 | 2010 | 1795 | 0.340 |
Why?
| | Receptors, Antigen, T-Cell | 4 | 2020 | 673 | 0.330 |
Why?
| | Gastrointestinal Diseases | 1 | 2013 | 221 | 0.330 |
Why?
| | Mice, Inbred C57BL | 7 | 2025 | 5972 | 0.310 |
Why?
| | Young Adult | 7 | 2026 | 14176 | 0.290 |
Why?
| | Immunotherapy, Adoptive | 3 | 2025 | 342 | 0.290 |
Why?
| | Th2 Cells | 4 | 2008 | 175 | 0.290 |
Why?
| | Glycolipids | 2 | 2007 | 53 | 0.290 |
Why?
| | Middle Aged | 12 | 2026 | 36126 | 0.280 |
Why?
| | Immunophenotyping | 2 | 2020 | 318 | 0.280 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2022 | 296 | 0.280 |
Why?
| | Adult | 14 | 2026 | 40665 | 0.280 |
Why?
| | Interleukin-2 Receptor alpha Subunit | 2 | 2026 | 82 | 0.270 |
Why?
| | Receptors, Chemokine | 1 | 2007 | 48 | 0.260 |
Why?
| | Immunosuppressive Agents | 2 | 2024 | 837 | 0.260 |
Why?
| | Multiple Myeloma | 2 | 2021 | 309 | 0.260 |
Why?
| | Aged | 10 | 2026 | 26096 | 0.250 |
Why?
| | Mice, Inbred NOD | 2 | 2025 | 613 | 0.220 |
Why?
| | Drug Synergism | 1 | 2025 | 354 | 0.220 |
Why?
| | Methotrexate | 1 | 2026 | 233 | 0.210 |
Why?
| | Bendamustine Hydrochloride | 1 | 2024 | 18 | 0.210 |
Why?
| | HLA-A2 Antigen | 1 | 2024 | 36 | 0.210 |
Why?
| | Survival Rate | 2 | 2019 | 2087 | 0.210 |
Why?
| | Adolescent | 5 | 2026 | 22479 | 0.200 |
Why?
| | Interleukin-2 | 2 | 2024 | 440 | 0.200 |
Why?
| | Male | 13 | 2026 | 72664 | 0.200 |
Why?
| | Encephalomyelitis, Autoimmune, Experimental | 1 | 2024 | 68 | 0.200 |
Why?
| | Female | 14 | 2026 | 78636 | 0.190 |
Why?
| | Antigens, CD | 2 | 2024 | 558 | 0.190 |
Why?
| | Lymphoma, Large B-Cell, Diffuse | 1 | 2024 | 193 | 0.170 |
Why?
| | Globulins | 1 | 2021 | 2 | 0.170 |
Why?
| | Disease Models, Animal | 5 | 2020 | 4552 | 0.170 |
Why?
| | Heterocyclic Compounds | 1 | 2021 | 23 | 0.170 |
Why?
| | Immunotherapy | 1 | 2026 | 665 | 0.170 |
Why?
| | Hymecromone | 1 | 2020 | 8 | 0.170 |
Why?
| | Chimerism | 1 | 2021 | 35 | 0.170 |
Why?
| | Autoimmune Diseases | 1 | 2025 | 468 | 0.160 |
Why?
| | Mice, Knockout | 5 | 2019 | 3114 | 0.160 |
Why?
| | Biological Products | 1 | 2024 | 257 | 0.160 |
Why?
| | Feasibility Studies | 1 | 2025 | 1109 | 0.160 |
Why?
| | Lymphoma, Mantle-Cell | 1 | 2020 | 35 | 0.160 |
Why?
| | Antibodies, Blocking | 1 | 2019 | 37 | 0.150 |
Why?
| | Immune Reconstitution | 1 | 2019 | 10 | 0.150 |
Why?
| | Immunity | 1 | 2020 | 140 | 0.150 |
Why?
| | Insulin-Secreting Cells | 1 | 2024 | 392 | 0.150 |
Why?
| | Antilymphocyte Serum | 1 | 2019 | 57 | 0.150 |
Why?
| | Lymphocyte Count | 1 | 2019 | 163 | 0.150 |
Why?
| | Clone Cells | 1 | 2020 | 263 | 0.150 |
Why?
| | Membrane Proteins | 2 | 2020 | 1163 | 0.150 |
Why?
| | Antigens | 2 | 2020 | 348 | 0.150 |
Why?
| | Cancer Vaccines | 1 | 2020 | 161 | 0.150 |
Why?
| | Severity of Illness Index | 2 | 2019 | 2928 | 0.140 |
Why?
| | Hyaluronic Acid | 1 | 2020 | 225 | 0.140 |
Why?
| | Allografts | 1 | 2019 | 151 | 0.140 |
Why?
| | Disease Susceptibility | 1 | 2020 | 343 | 0.140 |
Why?
| | Tissue Transplantation | 1 | 2017 | 10 | 0.130 |
Why?
| | Islets of Langerhans | 1 | 2024 | 846 | 0.130 |
Why?
| | STAT5 Transcription Factor | 1 | 2017 | 50 | 0.130 |
Why?
| | Dendritic Cells | 1 | 2020 | 496 | 0.130 |
Why?
| | Disease-Free Survival | 1 | 2019 | 766 | 0.130 |
Why?
| | Inflammation Mediators | 1 | 2019 | 506 | 0.120 |
Why?
| | Neoplasm, Residual | 3 | 2022 | 143 | 0.120 |
Why?
| | Adoptive Transfer | 2 | 2014 | 199 | 0.120 |
Why?
| | Histocompatibility Antigens Class I | 1 | 2017 | 202 | 0.120 |
Why?
| | Immunohistochemistry | 1 | 2019 | 1713 | 0.110 |
Why?
| | B-Lymphocytes | 1 | 2021 | 866 | 0.110 |
Why?
| | Antigens, Differentiation, T-Lymphocyte | 2 | 2008 | 104 | 0.110 |
Why?
| | Cell Line, Tumor | 2 | 2020 | 3539 | 0.110 |
Why?
| | Proteome | 1 | 2020 | 512 | 0.110 |
Why?
| | CD8-Positive T-Lymphocytes | 2 | 2020 | 917 | 0.110 |
Why?
| | Diabetes Mellitus, Type 1 | 2 | 2024 | 3918 | 0.110 |
Why?
| | Computational Biology | 1 | 2020 | 669 | 0.110 |
Why?
| | Cell Culture Techniques | 1 | 2017 | 372 | 0.110 |
Why?
| | Gene Expression | 1 | 2019 | 1474 | 0.110 |
Why?
| | Self Tolerance | 1 | 2014 | 26 | 0.100 |
Why?
| | Organ Transplantation | 1 | 2017 | 250 | 0.100 |
Why?
| | Ovalbumin | 4 | 2008 | 194 | 0.100 |
Why?
| | Hair Follicle | 1 | 2014 | 49 | 0.100 |
Why?
| | Cells, Cultured | 6 | 2020 | 4142 | 0.100 |
Why?
| | Proteomics | 1 | 2020 | 1185 | 0.090 |
Why?
| | Gene Expression Profiling | 1 | 2020 | 1763 | 0.090 |
Why?
| | Interleukin-17 | 2 | 2014 | 120 | 0.090 |
Why?
| | Acute Disease | 2 | 2026 | 1035 | 0.080 |
Why?
| | Induced Pluripotent Stem Cells | 1 | 2014 | 272 | 0.080 |
Why?
| | Transplantation, Autologous | 2 | 2021 | 298 | 0.070 |
Why?
| | Proteins | 2 | 2008 | 1022 | 0.070 |
Why?
| | Mice, Mutant Strains | 2 | 2008 | 302 | 0.070 |
Why?
| | Interleukin-10 | 3 | 2014 | 309 | 0.070 |
Why?
| | Interleukin-4 | 2 | 2008 | 207 | 0.070 |
Why?
| | Interleukin-13 | 2 | 2008 | 146 | 0.070 |
Why?
| | beta 2-Microglobulin | 1 | 2008 | 48 | 0.070 |
Why?
| | Antigens, CD1d | 1 | 2008 | 69 | 0.070 |
Why?
| | T-Lymphocytes, Helper-Inducer | 2 | 2015 | 132 | 0.070 |
Why?
| | Antineoplastic Agents | 1 | 2020 | 2207 | 0.070 |
Why?
| | Endothelial Cells | 1 | 2014 | 873 | 0.070 |
Why?
| | Chemokine CCL17 | 1 | 2007 | 6 | 0.070 |
Why?
| | Receptors, CCR4 | 1 | 2007 | 24 | 0.070 |
Why?
| | Chemokines, CC | 1 | 2007 | 33 | 0.070 |
Why?
| | Cell Movement | 2 | 2014 | 959 | 0.070 |
Why?
| | Ozone | 1 | 2008 | 115 | 0.060 |
Why?
| | Cell Differentiation | 1 | 2014 | 2040 | 0.060 |
Why?
| | Galactosylceramides | 1 | 2006 | 28 | 0.060 |
Why?
| | Cell Communication | 1 | 2008 | 328 | 0.060 |
Why?
| | Mice, Transgenic | 4 | 2015 | 2185 | 0.060 |
Why?
| | Immunologic Memory | 2 | 2020 | 368 | 0.060 |
Why?
| | Cell Proliferation | 3 | 2020 | 2504 | 0.060 |
Why?
| | Cytokines | 3 | 2008 | 2048 | 0.050 |
Why?
| | Apoptosis | 2 | 2010 | 2434 | 0.050 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2021 | 847 | 0.050 |
Why?
| | Neoplasms | 1 | 2020 | 2900 | 0.050 |
Why?
| | Glucuronidase | 1 | 2024 | 27 | 0.050 |
Why?
| | Retrospective Studies | 4 | 2026 | 17247 | 0.050 |
Why?
| | Antigens, CD19 | 1 | 2024 | 128 | 0.050 |
Why?
| | Eosinophilia | 1 | 2006 | 223 | 0.050 |
Why?
| | Air Pollutants | 1 | 2008 | 405 | 0.050 |
Why?
| | Allergens | 2 | 2002 | 386 | 0.050 |
Why?
| | Bone Marrow Examination | 1 | 2021 | 5 | 0.040 |
Why?
| | Benzylamines | 1 | 2021 | 44 | 0.040 |
Why?
| | Hematopoietic Stem Cell Mobilization | 1 | 2021 | 28 | 0.040 |
Why?
| | Antigens, CD34 | 1 | 2021 | 89 | 0.040 |
Why?
| | Cricetulus | 1 | 2021 | 118 | 0.040 |
Why?
| | Sensitivity and Specificity | 1 | 2026 | 1995 | 0.040 |
Why?
| | Immunization, Passive | 1 | 2021 | 90 | 0.040 |
Why?
| | CHO Cells | 1 | 2021 | 169 | 0.040 |
Why?
| | Granulocyte Colony-Stimulating Factor | 1 | 2021 | 90 | 0.040 |
Why?
| | Cryopreservation | 1 | 2022 | 113 | 0.040 |
Why?
| | Pancreas Transplantation | 1 | 2020 | 71 | 0.040 |
Why?
| | Cyclophosphamide | 1 | 2021 | 266 | 0.040 |
Why?
| | Oligodeoxyribonucleotides | 1 | 2020 | 141 | 0.040 |
Why?
| | Endpoint Determination | 1 | 2020 | 85 | 0.040 |
Why?
| | Cell Engineering | 1 | 2020 | 15 | 0.040 |
Why?
| | Jurkat Cells | 1 | 2020 | 115 | 0.040 |
Why?
| | Bone Marrow | 1 | 2021 | 306 | 0.040 |
Why?
| | Gene Library | 1 | 2020 | 122 | 0.040 |
Why?
| | Zika Virus | 1 | 2021 | 136 | 0.040 |
Why?
| | Antigen Presentation | 1 | 2020 | 207 | 0.040 |
Why?
| | Unrelated Donors | 1 | 2019 | 39 | 0.040 |
Why?
| | Extracellular Matrix | 1 | 2024 | 561 | 0.040 |
Why?
| | Bronchoalveolar Lavage Fluid | 3 | 2008 | 638 | 0.040 |
Why?
| | Leukocytes | 1 | 2020 | 296 | 0.040 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 1 | 2020 | 153 | 0.040 |
Why?
| | B7-H1 Antigen | 1 | 2020 | 243 | 0.030 |
Why?
| | Algorithms | 1 | 2026 | 1845 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2020 | 968 | 0.030 |
Why?
| | Viruses | 1 | 2020 | 164 | 0.030 |
Why?
| | Recombinant Proteins | 1 | 2021 | 1368 | 0.030 |
Why?
| | Antibodies, Viral | 1 | 2021 | 673 | 0.030 |
Why?
| | Inducible T-Cell Co-Stimulator Ligand | 2 | 2008 | 4 | 0.030 |
Why?
| | Inducible T-Cell Co-Stimulator Protein | 2 | 2008 | 12 | 0.030 |
Why?
| | Cytoprotection | 1 | 2015 | 56 | 0.030 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2022 | 1146 | 0.030 |
Why?
| | Treatment Outcome | 2 | 2020 | 11741 | 0.030 |
Why?
| | Perforin | 1 | 2014 | 22 | 0.030 |
Why?
| | Heart Transplantation | 1 | 2020 | 675 | 0.030 |
Why?
| | Receptors, CCR7 | 1 | 2014 | 32 | 0.030 |
Why?
| | Granzymes | 1 | 2014 | 49 | 0.030 |
Why?
| | CD4 Lymphocyte Count | 1 | 2014 | 280 | 0.030 |
Why?
| | Ligands | 2 | 2008 | 664 | 0.020 |
Why?
| | Melanoma | 1 | 2020 | 759 | 0.020 |
Why?
| | Pandemics | 1 | 2022 | 1703 | 0.020 |
Why?
| | Psoriasis | 1 | 2014 | 115 | 0.020 |
Why?
| | Lung | 1 | 2006 | 4101 | 0.020 |
Why?
| | Risk Factors | 1 | 2026 | 10857 | 0.020 |
Why?
| | Aorta | 1 | 2014 | 439 | 0.020 |
Why?
| | Prognosis | 1 | 2019 | 4310 | 0.020 |
Why?
| | Phosphatidylserines | 1 | 2010 | 62 | 0.020 |
Why?
| | Cell Separation | 1 | 2010 | 304 | 0.020 |
Why?
| | Microscopy, Confocal | 1 | 2010 | 318 | 0.020 |
Why?
| | Skin | 1 | 2014 | 753 | 0.020 |
Why?
| | Hospitalization | 1 | 2019 | 2458 | 0.020 |
Why?
| | Prospective Studies | 1 | 2021 | 8035 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 977 | 0.020 |
Why?
| | Leukocyte Count | 1 | 2008 | 316 | 0.020 |
Why?
| | Flow Cytometry | 1 | 2010 | 1159 | 0.020 |
Why?
| | Phenotype | 1 | 2014 | 3138 | 0.010 |
Why?
| | Hypersensitivity | 1 | 2007 | 254 | 0.010 |
Why?
| | Methacholine Chloride | 1 | 2002 | 51 | 0.010 |
Why?
| | Pulmonary Eosinophilia | 1 | 2002 | 27 | 0.010 |
Why?
| | Transduction, Genetic | 1 | 2002 | 132 | 0.010 |
Why?
| | Mice, SCID | 1 | 2002 | 369 | 0.010 |
Why?
| | Protein Engineering | 1 | 2002 | 122 | 0.010 |
Why?
| | Genetic Therapy | 1 | 2002 | 315 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2002 | 2026 | 0.010 |
Why?
| | Cell Line | 1 | 2002 | 2821 | 0.010 |
Why?
| | Inflammation | 1 | 2002 | 2876 | 0.010 |
Why?
|
|
Meyer's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|